Tango Therapeutics press release (TNGX): Q2 GAAP EPS of -$0.37 misses by $0.05. As of June 30, 2026, the Company held $1.0 billion in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan To ensure this doesnâ
Tango Therapeutics press release (TNGX): Q2 GAAP EPS of -$0.37 misses by $0.05.
As of June 30, 2026, the Company held $1.0 billion in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
